ArticleCureus2023
Managing a Patient Presenting With Chest Pain and Gastrointestinal Complaints Using Dupilumab.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse drug reactions or adverse drug events account for a significant proportion of emergency department visits among children and adolescents. Unfortunately, rare reactions to medications may go unnoticed by clinicians due to a lack of reporting to drug surveillance and monitoring programs. We present the case of an 18-year-old male who visited the emergency department on two separate occasions after receiving dupilumab injections for his atopic dermatitis. Ten days prior to his presentation, he was evaluated in the emergency room for the onset of chest pain, five days following his first dupilumab injection. Investigations in the interim revealed no cardiac pathology. He presented with a complaint of severe abdominal pain associated with nausea and vomiting several hours after receiving his second dupilumab injection. Investigations for causes of acute gastrointestinal or anaphylactic reactions only revealed mild leukocytosis and hypokalemia. A definitive diagnosis of hypersensitivity reaction, such as anaphylaxis or serum-sickness-like reaction, could not be made at either emergency visit due to the lack of objective findings and few similar reported cases. However, the timing of each event made an adverse reaction highly suspicious as the inciting factor of this patient's symptoms. He received oral potassium, ketorolac, and ondansetron for headache and ongoing nausea respectively. He was discharged home within a few hours after his symptoms had resolved. The limited reports and evidence of these symptoms being associated with dupilumab injections made it difficult to reach a definitive diagnosis. However, a holistic review of the patient's history, medication list, and contextual factors revealed that a rare adverse drug reaction was a possible inciting factor on each separate occasion. Further research is required to determine the frequency and explore the existence of any causal relationship between dupilumab treatment and chest pain or gastritis in adolescent populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.